Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07624526
PHASE4

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Sponsor: Emory University

View on ClinicalTrials.gov

Summary

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Key Details

Gender

All

Age Range

18 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2026-07

Completion Date

2028-08

Last Updated

2026-06-03

Healthy Volunteers

No

Interventions

DRUG

Suzetrigine

Suzetrigine is an orally administered, selective NaV1.8 voltage-gated sodium channel inhibitor being investigated as a non-opioid analgesic for the treatment of pain through inhibition of pain signal transmission in peripheral sensory neurons.

Locations (3)

Emory Clinic

Atlanta, Georgia, United States

Emory Clinic at Executive Park

Atlanta, Georgia, United States

Emory Orthopaedics and Spine Center

Atlanta, Georgia, United States